Overview

Chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are driven by the BCR-ABL fusion kinase, and tyrosine kinase inhibitors (TKIs) have transformed their outlook. Yet resistance remains a central problem, most notoriously through the T315I "gatekeeper" mutation. Ponatinib, a third-generation BCR-ABL inhibitor, was designed specifically to retain activity against this resistant variant, making it a pivotal option when earlier TKIs fail.

How Resistance Arises at the Kinase Domain

More than 100 point mutations in the BCR-ABL kinase domain have been identified, together accounting for a substantial share of TKI resistance. The most consequential single alteration is T315I, a substitution that replaces threonine with the bulky isoleucine at position 315. This "gatekeeper" residue normally helps form a hydrogen bond with many inhibitors; the isoleucine both removes that bond and creates steric hindrance, blocking the binding of imatinib, nilotinib and dasatinib alike.

Ponatinib's Distinct Binding Scaffold

Ponatinib was engineered with a scaffold that does not require a hydrogen bond at residue 315. Its extended ethynyl linkage allows it to accommodate the bulky isoleucine side chain, so it inhibits both wild-type and T315I-mutated BCR-ABL. Beyond BCR-ABL, ponatinib also inhibits related kinases including FGFR, VEGFR, PDGFR, KIT and Src family kinases, a broader profile that informs its activity across resistant disease states.

Clinical Position in Resistant Disease

Ponatinib is indicated for T315I-mutated CML, for CML resistant to or intolerant of prior TKIs, for advanced-phase CML, and for T315I-mutated or resistant Ph+ ALL. Because the T315I mutation predicts failure of earlier agents, mutation testing to detect it guides appropriate use. In this sense ponatinib is the therapy that closes the resistance gap left by first- and second-generation TKIs.

FAQ

Q: What makes the T315I mutation so resistant? A: The isoleucine substitution blocks the hydrogen bond and creates steric hindrance that prevents imatinib, nilotinib and dasatinib from binding BCR-ABL.

Q: How does ponatinib beat the gatekeeper mutation? A: Its binding scaffold does not depend on the T315 hydrogen bond and tolerates the bulky isoleucine, inhibiting both wild-type and T315I BCR-ABL.

Q: When is ponatinib indicated? A: For T315I-mutated CML, CML resistant or intolerant to prior TKIs, advanced-phase CML, and T315I-mutated or resistant Ph+ ALL.

Q: What strength and pack are referenced? A: The 15 mg capsule strength in a 60-capsule pack is the configuration referenced for this product.